Abstract B148: Ultrasound image guided combination therapies involving photodynamic therapy and irinotecan.

Srivalleesha Mallidi(Tufts University), Tayyaba Hasan(Harvard University), Imran Rizvi(King George's Medical University), Dmitriy Timerman(Harvard University), Ruth Goldschmidt(California Institute of Technology), Joyce F. Liu(Duke University), Bryan Q. Spring(Northeastern University), Zhiming Mai(MGH Institute of Health Professions), Huang‐Chiao Huang(University of Maryland, Baltimore), Patrick Yin Chiang(Fudan University), Akilan Palanisami(Harvard University)
Molecular Cancer Therapeutics
November 1, 2013
10.1158/1535-7163.targ-13-b148
Cited by 0

Related Papers

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
|Oncotarget|2016|627
Inorganic nanoparticles for cancer imaging and therapy
|Journal of Controlled Release|2011|599
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
|The Lancet Oncology|2014|586